Françoise Barré-Sinoussi was born on 30 July 1947 in the 19th arrondissement of Paris, the only child of Roger Sinoussi, who worked in the building trade, and Jeanine Fau Sinoussi. Paris remained her home, but the summers that shaped her were spent in the Auvergne countryside. There she watched insects and animals for hours, comparing how they moved and lived. That early habit of looking closely at living things became the thread of her career.
At school she was stronger in science than in languages or philosophy. After her baccalauréat in 1966 she hesitated between medicine and biomedical science. Medicine seemed longer and more expensive for a family of modest means, so she chose the Faculty of Sciences at the University of Paris. After two years of lectures she grew impatient. She wanted to know what laboratory work actually felt like. For nearly a year she asked laboratories to take her as a volunteer. Most refused. In 1971 Jean-Claude Chermann’s group at the Institut Pasteur in Garches accepted her. The lab was studying retroviruses that caused leukemia in mice, work that had become possible after the discovery of reverse transcriptase in 1970.
She spent so much time at the bench that she appeared on campus mainly for exams. Chermann encouraged her to stay for a doctorate. Her thesis examined a synthetic molecule, HPA23, and its effect on Friend virus-induced leukemia in mice. She received her PhD from the University of Paris in 1974 (some accounts give 1975). A year of postdoctoral work followed at the National Cancer Institute of the National Institutes of Health in the United States. Then she returned to Pasteur, still with Chermann, now inside the department headed by Luc Montagnier. The group was one of the few still linking retroviruses to cancer after the field had shifted toward oncogenes.
In late 1982 the clinician Willy Rozenbaum contacted Pasteur. A new syndrome, first noticed among gay men in the United States and now appearing in France, destroyed the immune system. Could a retrovirus be responsible? Montagnier asked Barré-Sinoussi whether the lab had the tools to look. It did. In January 1983 a lymph-node biopsy from a patient at risk arrived. Barré-Sinoussi cultured the lymphocytes and, within weeks, detected reverse-transcriptase activity in the supernatant. The virus did not react with reagents for HTLV-1, the only known human retrovirus at the time. Electron microscopy by Charles Dauguet showed the particles. The team named the isolate lymphadenopathy-associated virus, or LAV. Their paper appeared in Science in May 1983. Barré-Sinoussi presented the findings at Cold Spring Harbor and then at the CDC and NIH. Further characterization, including sequencing by Pasteur molecular biologists, and clinical correlations convinced the community that LAV, later renamed human immunodeficiency virus, was the cause of AIDS.
The discovery made blood tests possible and, in time, made antiretroviral therapy possible. AIDS shifted from an almost uniform death sentence to a chronic, manageable condition for those who could obtain the drugs. Barré-Sinoussi did not treat the laboratory result as the end of the story. In 1985 she went to a World Health Organization workshop in Bangui, Central African Republic. The scale of illness and the poverty of the hospitals shocked her. From then on she treated collaboration with resource-limited countries as part of the science. She worked in Africa and later in Vietnam and Cambodia, helping set up diagnostic capacity and training. She helped organize the 1986 International AIDS Conference in Paris and was among those who formed the International AIDS Society.
She remained at Pasteur after Chermann left in 1987. In 1988 she began her own programs on viral and host determinants of pathogenesis. In 1992 she became head of the Biology of Retroviruses Unit, later renamed the Regulation of Retroviral Infections Unit. The group studied how some people control infection, how T-cell activation harms the host, and what immune correlates might guide vaccines or immunotherapy. She published hundreds of papers, trained younger scientists, and sat on national and international advisory bodies, including France’s National Agency for AIDS Research.
Recognition accumulated. She received the King Faisal International Prize for Medicine in 1993, French Academy of Medicine honors, and national orders culminating in the Grand Cross of the Legion of Honour. In 2008 she and Montagnier shared half of the Nobel Prize in Physiology or Medicine “for their discovery of human immunodeficiency virus.” Harald zur Hausen received the other half for work on human papillomavirus and cervical cancer. Barré-Sinoussi was the first French woman to win the medicine prize. She used the platform to insist that the isolation of HIV had been a collective effort of clinicians, virologists, and molecular biologists, and that the remaining task was access to treatment and prevention for people still dying of AIDS.
She served as president of the International AIDS Society from 2012 to 2014 and launched its “Towards an HIV Cure” initiative. She has been president of the French association Sidaction. In 2020 the French presidency asked her to chair the Comité analyse recherche et expertise during the COVID-19 pandemic. After mandatory retirement from her Pasteur laboratory around 2015 she continued as honorary president of the Pasteur international network and of the virology department, and as a member of scientific boards.
Barré-Sinoussi has often said that contact with people living with HIV was her motivation from the start. She attended early meetings of the French association AIDES, listened to patients describe stigma inside hospitals, and later argued that activists, not scientists alone, forced down the price of drugs and opened the way for generics in poor countries. She criticized public statements that undermined condom use. She visited countries where homosexuality or sex work was criminalized and pressed for policies based on evidence rather than moral panic.
Her life is a single arc: a child watching insects in the Auvergne, a volunteer who found a bench at Pasteur, a 35-year-old who saw reverse-transcriptase activity in a culture flask, and a scientist who refused to separate discovery from the people the virus was killing. The virus she helped isolate still infects millions. Treatments exist. A sterilizing vaccine and a scalable cure do not. Barré-Sinoussi’s public message has been consistent: the science is unfinished until prevention and care reach the places where the epidemic still does the most harm.